REGENXBIO Inc. growth

Reported trailing growth, forward expectations and three-year compound growth rates.

Trailing growth

Year over year

Revenue: -44.0%
EBITDA: -87.3%
EBIT: -63.1%
EPS: -80.1%
Free cash flow: —
Operating cash flow: —

Forward estimates

Revenue: +101.6%
EBITDA: +49.6%
EPS: +39.1%

Three-year CAGR

Revenue: +14.8%
EBITDA: +32.8%
EBIT: +30.9%
Net income: +14.6%
EPS: +18.1%
Free cash flow: +28.0%

Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.